Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 433

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Bendamustine in Combination With Rituximab for Previously Untreated Patients With Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group

Fischer, Kirsten, Cramer, Paula, Busch, Raymonde, Böttcher, Sebastian, Bahlo, Jasmin, Schubert, Jöerg, Pflüger, Karl H., Schott, Silke, Goede, Valentin, Isfort, Susanne, von Tresckow, Julia, Fink, Anna-Maria, Bühler, Andreas, Winkler, Dirk, Kreuzer, Karl-Anton, Staib, Peter, Ritgen, Matthias, Kneba, Michael, Döhner, Hartmut, Eichhorst, Barbara F., Hallek, Michael, Stilgenbauer, Stephan, Wendtner, Clemens-Martin·2012·Journal of Clinical Oncology

Abstract

Purpose: We investigated the safety and efficacy of bendamustine and rituximab (BR) in previously untreated patients with chronic lymphocytic leukemia (CLL). Patients and Methods: In all, 117 patients, age 34 to 78 years, 46.2% of patients at Binet stage C, and 25.6% of patients age 70 years or older received BR chemoimmunotherapy for first-line treatment of CLL. Bendamustine was administered at a dose of 90 mg/m 2 on days 1 and 2 combined with 375 mg/m 2 rituximab on day 0 of the first course and 500 mg/m 2 on day 1 during subsequent courses for up to six courses. Results: Overall response rate was 88.0% (95% CI, 80.7% to 100.0%) with a complete response rate of 23.1% and a partial response rate of 64.9%. Ninety percent of patients with del(11q), 94.7% with trisomy 12, 37.5% with del(17p), and 89.4% with unmutated IGHV status responded to treatment. After a median observation time of 27.0 months, median event-free survival was 33.9 months, and 90.5% of patients were alive. Grade 3 or 4 severe infections occurred in 7.7% of patients. Grade 3 or 4 adverse events for neutropenia, thrombocytopenia, and anemia were documented in 19.7%, 22.2%, and 19.7% of patients, respectively. Conclusion: Chemoimmunotherapy with BR is effective and safe in patients with previously untreated CLL.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2011.39.2688

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 23 references

Cited by

See all 433

Metadata

Authors
Fischer, K., Cramer, P., Busch, R., Böttcher, S., Bahlo, J., Schubert, J., Pflüger, K. H., Schott, S., Goede, V., Isfort, S., von Tresckow, J., Fink, A.-M., Bühler, A., Winkler, D., Kreuzer, K.-A., Staib, P., Ritgen, M., Kneba, M., Döhner, H., Eichhorst, B. F., Hallek, M., Stilgenbauer, S., & Wendtner, C.-M.
Venue
Journal of Clinical Oncology
Published
2012-09-10
Volume
30
Issue
26
Pages
3209-3216
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2144617723
Cited by
433
References
23
FWCI
22.21
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Bendamustine in Combination With Rituximab for Previously Untreated Patients With Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group. https://app.cochat.ai/papers/10.1200/jco.2011.39.2688
The paper
Fischer, K., Cramer, P., Busch, R., Böttcher, S., Bahlo, J., Schubert, J., Pflüger, K. H., Schott, S., Goede, V., Isfort, S., von Tresckow, J., Fink, A.-M., Bühler, A., Winkler, D., Kreuzer, K.-A., Staib, P., Ritgen, M., Kneba, M., Döhner, H., . . . Wendtner, C.-M. (2012). Bendamustine in Combination With Rituximab for Previously Untreated Patients With Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2011.39.2688

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.